Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2021-01-05 Regulatory Filings
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
Regulatory Filings Classification · 95% confidence The document is a press release dated January 5, 2021, announcing the design of a Phase III clinical trial for the drug candidate lanifibranor in NASH. It details clinical endpoints, regulatory discussions (FDA/EMA), trial size, and includes quotes from management and background information on the company and drug. This content structure—announcing significant operational/clinical milestones, often summarizing data or plans—is characteristic of an Earnings Release (ER) or a general press release that doesn't fit a specific financial filing category like 10-K or IR. Since it is a detailed announcement of clinical trial progress and strategy, it is best classified as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's a standalone announcement. However, given the focus on clinical development updates, which often accompany or substitute for formal financial reporting highlights in biotech, and the lack of specific financial tables (beyond Phase IIb results), it functions as a major operational update. In the context of the provided definitions, this is a significant corporate announcement that doesn't fit the specific financial reports (10-K, IR, MRQ) or specific corporate actions (DIV, CAP, SHA). It is a press release detailing operational/clinical progress. Since 'ER' is defined as the 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this document focuses heavily on clinical trial design rather than financial results highlights, the most appropriate general category for a significant, non-standard regulatory announcement is RNS, or potentially ER if we interpret 'key highlights' broadly to include major clinical milestones that drive future earnings potential. Given the strong focus on clinical trial design and regulatory interaction, it is a significant corporate announcement. If it were purely financial highlights, ER would fit. As it is a major clinical update press release, RNS (Regulatory Filings / miscellaneous) is a strong candidate, but often these clinical updates are issued alongside or in lieu of ERs. Given the document length and content depth, it is more substantial than a typical RNS 'notice'. Let's re-evaluate ER: 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document contains no quarterly financial highlights, only Phase IIb results used to justify Phase III design. Therefore, RNS is the most appropriate fallback for a detailed, non-standard corporate/clinical press release.
2021-01-05 English
Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis
Regulatory Filings Classification · 95% confidence The document is explicitly titled '# **PRESS RELEASE**' and begins by announcing the 'publication in the *Journal of Hepatology* of new pre-clinical data'. It details the findings and includes quotes from management and co-authors, concluding with contact information and standard forward-looking statements typical of a corporate press release. This structure indicates an initial announcement of results or findings, rather than the full regulatory report itself (like 10-K or IR). Since it is an announcement of scientific/research results, it fits best under the 'Earnings Release' (ER) category if it were financial results, but since it is a scientific publication announcement, and given the available options, it is most closely aligned with a general announcement. However, the core function is to disseminate key findings immediately. If this were a financial earnings announcement, it would be ER. Since it is a scientific/data announcement, and there isn't a specific 'Scientific Publication Announcement' code, we must evaluate the closest fit. It is not a proxy statement (DEF 14A), a formal report (10-K/IR), or a management discussion (MDA). Given the context of a biopharma company announcing positive data publication, this functions similarly to an Earnings Release (ER) in terms of immediacy and highlighting key performance indicators (data milestones). Alternatively, it could be a Regulatory Filing (RNS) as a general announcement. Given the content is a press release announcing data, and not a formal regulatory filing like a 10-Q/K, 'ER' is often used for initial results announcements, but 'RNS' is the best fallback for non-standard announcements. Since the document is a full press release (not just a short notice stating a report is attached), it is not RPA. I will classify it as a Regulatory Filing (RNS) as it is a general corporate announcement that doesn't fit the specific financial/governance codes, although it shares characteristics with an ER.
2020-12-07 English
Inventiva annonce la publication dans la revue « Journal of Hepatology » de nouvelles données pré-cliniques démontrant les effets bénéfiques de lanifibranor sur la cirrhose
Regulatory Filings Classification · 95% confidence The document is a press release dated December 7, 2020, announcing that new preclinical data regarding the drug lanifibranor and its effects on cirrhosis have been published in the scientific journal *'Journal of Hepatology'*. The text details the scientific findings, includes quotes from the Scientific Director and a co-author, and provides publication details (title, date, authors, link). This is not a formal regulatory filing like a 10-K or an IR, nor is it a general earnings release (ER). It is an announcement specifically about the publication of scientific/research results. This fits best under the category for general regulatory announcements or miscellaneous filings that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially a specific type of Investor Presentation (IP) if it were a slide deck, but since it's an announcement of a scientific publication, RNS is the most appropriate general category for this type of corporate news release that isn't a core financial report or management change.
2020-12-07 French
Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Investor Presentation Classification · 95% confidence The document is a press release dated November 24, 2020, announcing that the company, Inventiva, will participate in the 'Piper Sandler 32nd Annual Virtual Healthcare Conference' through 1x1 investor meetings and a fire-side chat. This type of announcement, detailing participation in an external investor event (like a conference presentation or meeting schedule), is typically classified as an Investor Presentation (IP) or, more broadly, a communication aimed at investors regarding corporate activities. Since it is not the presentation material itself, but an announcement about future investor engagement, it aligns best with the purpose of investor communications. Given the options, 'Investor Presentation' (IP) is the closest fit for an announcement detailing participation in a major investor conference where presentations/discussions occur, although 'Regulatory Filings' (RNS) could also be considered if the primary focus was just the announcement mechanism. However, because the content is entirely focused on investor engagement and presentation schedules, IP is the most specific and appropriate classification.
2020-11-24 English
Inventiva annonce sa participation à la « Piper Sandler 32nd Annual Virtual Healthcare Conference »
Report Publication Announcement Classification · 99% confidence The document is a press release from Inventiva announcing its participation in the 'Piper Sandler 32nd Annual Virtual Healthcare Conference'. It details the format (analyst discussion), speakers, and provides a link to the replay. This type of announcement, which promotes the company's presence at an external investor event (like a conference presentation or discussion), is best classified as an Investor Presentation (IP) if the content discussed is the presentation itself, or, more accurately in this context where it's an announcement *about* participation and providing access to the discussion, it relates closely to investor outreach materials. Since the document provides details about an analyst discussion and links to access it, and the context is clearly focused on communicating with investors about company activities and pipeline updates (which often accompany such events), 'Investor Presentation' (IP) is the most fitting category among the choices, as it relates to materials shared with investors. It is not a formal regulatory filing like 10-K or ER, nor is it a general regulatory announcement (RNS). Given the content focuses on an investor-facing event, IP is appropriate.
2020-11-24 French
Information financière du 3ème trimestre 2020
Earnings Release Classification · 98% confidence The document is explicitly titled as a press release ("COMMUNIQUE DE PRESSE") and focuses on providing key financial highlights for the third quarter of 2020 ("Information financière du 3 ème trimestre 2020"), including cash position and revenue for the first nine months of 2020. It also outlines upcoming clinical milestones and investor conference participation. This structure—a brief announcement of period-end financial results (cash and revenue) without the full detail expected in a comprehensive report like an Annual Report (10-K) or a full Interim Report (IR)—is characteristic of an Earnings Release (ER). The document is dated November 12, 2020, reporting on the period ending September 30, 2020, which confirms it is a periodic earnings announcement. 9M 2020
2020-11-12 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.